These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 10078591)

  • 21. Effects of either tibolone or continuous combined transdermal estradiol with medroxyprogesterone acetate on coagulatory factors and lipoprotein(a) in menopause.
    Perrone G; Capri O; Galoppi P; Brunelli R; Bevilacqua E; Ceci F; Ciarla MV; Strom R
    Gynecol Obstet Invest; 2009; 68(1):33-9. PubMed ID: 19349712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Continuous combined hormone replacement therapy with oral 17beta-estradiol and norethisterone acetate improves homocysteine metabolism in postmenopausal women.
    Ventura P; Cagnacci A; Malmusi S; Panini R; Baldassari F; Arangino S; Volpe A; Salvioli G
    Menopause; 2001; 8(4):252-8. PubMed ID: 11449082
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term effects of oral and transdermal hormone replacement therapy on plasma homocysteine levels.
    Chiantera V; Sarti CD; Fornaro F; Farzati A; De Franciscis P; Sepe E; Borrelli AL; Colacurci N
    Menopause; 2003; 10(4):286-91. PubMed ID: 12851511
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential effect of transdermal estrogen plus progestagen replacement therapy on insulin metabolism in postmenopausal women: relation to their insulinemic secretion.
    Cucinelli F; Paparella P; Soranna L; Barini A; Cinque B; Mancuso S; Lanzone A
    Eur J Endocrinol; 1999 Mar; 140(3):215-23. PubMed ID: 10216516
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transdermal estrogen reduces vascular resistance and serum cholesterol in postmenopausal women.
    West SG; Hinderliter AL; Wells EC; Girdler SS; Light KC
    Am J Obstet Gynecol; 2001 Apr; 184(5):926-33. PubMed ID: 11303200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Postmenopausal hormone replacement therapy and insulin metabolism: effects of route of administration and implications for heart disease and diabetes risk.
    Godsland IF; Stevenson JC
    Br J Clin Pract Suppl; 1996 Sep; 86():1-5. PubMed ID: 8995002
    [No Abstract]   [Full Text] [Related]  

  • 27. Bhathena RK, Anklesaria BS, Ganatra AM, Pinto R. The influence of transdermal oestradiol replacement therapy and medroxyprogesterone acetate on serum lipids and lipoproteins. Br J Clin Pharmacol 1998 Feb; 45 (2): 170-172.
    Kneer-Aronoff C
    J Womens Health; 1998 Oct; 7(8):1054-5. PubMed ID: 10026007
    [No Abstract]   [Full Text] [Related]  

  • 28. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus.
    Andersson B; Mattsson LA; Hahn L; Mårin P; Lapidus L; Holm G; Bengtsson BA; Björntorp P
    J Clin Endocrinol Metab; 1997 Feb; 82(2):638-43. PubMed ID: 9024268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hormone replacement therapy does not affect plasma homocysteine in postmenopausal women with coronary artery disease. Free tissue factor pathway inhibitor antigen, a circulating anticoagulant, is related to plasma homocysteine.
    Os I; Os A; Sandset PM; Bølling S; Seljeflot I; Djurovic S; Westheim A
    Cardiology; 2002; 98(1-2):6-12. PubMed ID: 12373040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of the route of estrogen administration on insulinlike growth factor-I, IGF binding protein-3, and insulin resistance in healthy postmenopausal women: results from a randomized, controlled study.
    Davis SR; Stuckey BG; Norman RJ; Papalia MA; Drillich A; Bell RJ
    Menopause; 2008; 15(6):1065-9. PubMed ID: 18806686
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transdermal estradiol. A potentially improved method of hormone replacement.
    Judd HL
    J Reprod Med; 1994 May; 39(5):343-52. PubMed ID: 8064701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increase in circulating levels of cardiac natriuretic peptides after hormone replacement therapy in postmenopausal women.
    Maffei S; Del Ry S; Prontera C; Clerico A
    Clin Sci (Lond); 2001 Nov; 101(5):447-53. PubMed ID: 11672449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hormone replacement therapy: current controversies.
    Orija IB; Mehta A
    Clin Endocrinol (Oxf); 2003 Nov; 59(5):657. PubMed ID: 14616894
    [No Abstract]   [Full Text] [Related]  

  • 34. Use of transdermal oestradiol (Estraderm TTS) in hypertensive postmenopausal women.
    Foidart JM
    Br J Clin Pract Suppl; 1996 Sep; 86():14-6. PubMed ID: 8995005
    [No Abstract]   [Full Text] [Related]  

  • 35. A comparison of effects of sequential transdermal administration versus oral administration of estradiol plus norethisterone acetate on serum NO levels in postmenopausal women.
    Kurtay G; Ozmen B; Erguder I
    Maturitas; 2006 Jan; 53(1):32-8. PubMed ID: 16325022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of estrogen therapy on insulin resistance and plasminogen activator inhibitor type 1 concentrations in postmenopausal women.
    Saucedo R; Basurto L; Zarate A; Martínez C; Hernandez M; Galván R
    Gynecol Obstet Invest; 2007; 64(2):61-4. PubMed ID: 17264514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Balancing between observational studies and randomized trials in prevention of coronary heart disease by estrogen replacement: HERS study was no revolution.
    Ylikorkala O
    Acta Obstet Gynecol Scand; 2000 Dec; 79(12):1029-36. PubMed ID: 11130082
    [No Abstract]   [Full Text] [Related]  

  • 38. Nitric oxide in postmenopausal women taking three different HRT regimens.
    Kesim MD; Aydin Y; Erdemir M; Atis A
    Maturitas; 2005 Jan; 50(1):52-7. PubMed ID: 15590214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipid lowering therapy in women at risk of coronary disease.
    Davis SR; Newman A
    Clin Endocrinol (Oxf); 1999 Mar; 50(3):405-6. PubMed ID: 10435069
    [No Abstract]   [Full Text] [Related]  

  • 40. Transdermal estrogen replacement therapy: beneficial effects on hemostatic risk factors for cardiovascular disease.
    Lindoff C; Peterson F; Lecander I; Martinsson G; Astedt B
    Maturitas; 1996 May; 24(1-2):43-50. PubMed ID: 8794433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.